Ir para o conteúdo principal

Evolus (NASDAQ: EOLS) — Perfil da empresa, notícias e dados financeiros

Logo de Evolus
EOLS Evolus
Evolus primary media
Perfil da empresa

Evolus

Evolus (NASDAQ:EOLS) is a performance beauty company with a focus on medical aesthetics. The company's flagship product, Jeuveau®, aims to enhance the aesthetic appearance of consumers by reducing the appearance of facial lines and wrinkles. Evolus is committed to innovation in the rapidly growing aesthetics market, seeking to deliver advanced products that meet the evolving needs of its customers. With a customer-centric approach, the company is dedicated to providing top-tier service and support to its practitioners and their clients, ensuring a positive experience with their treatments. Evolus's objective is to be at the forefront of the beauty industry by expanding its product offerings and presence in the global market, emphasizing safety, quality, and customer satisfaction.

Resumo

Public USParticipação acionária
2012Ano de fundação
296Funcionários
Newport Beach, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Newport Beach, US

Produtos e/ou serviços de Evolus

  • Jeuveau, a proprietary formulation of prabotulinumtoxinA-xvfs for temporary improvement of moderate to severe frown lines.
  • Customer loyalty programs aimed to enhance patient retention and satisfaction for Jeuveau treatments.
  • Strategic partnership initiatives for market expansion and distribution of Jeuveau in international territories.
  • Investment in research and development to improve existing formulations and explore new applications for botulinum toxin products.
  • Digital marketing campaigns and educational programs to increase brand awareness and product knowledge among healthcare professionals.
  • Development and implementation of a state-of-the-art customer service platform to streamline the ordering process and support for medical practitioners.

equipe executiva do Evolus

  • David MoatazediPresident, CEO & Director
  • Tatjana MitchellChief Financial Officer
  • Rui AvelarChief Medical Officer and Head of Research & Development
  • Nareg SagherianHead of Global Investor Relations & Corporate Communications
  • Kurt KnabSenior Vice President of Sales
  • Jessica NovakSenior Vice President of Human Resources
  • Jeffrey J. PlumerCorporate Secretary

Principais indicadores financeiros

Resultados divulgados pela Evolus, em USD.

Cap. de mercado
463,3 mi
Receita (TTM)
325,5 mi
P/L
—
LPA (diluído, TTM)
-0.5
Dividend yield
—
Margem de lucro
-9.6%
Receita e lucro anuais da Evolus
Fim do ano fiscalReceitaResultado operacionalLucro líquido
297,2 mi-37,6 mi-51,6 mi
266,3 mi-34,4 mi-50,4 mi
202,1 mi-49,2 mi-61,7 mi
148,6 mi-65,3 mi-74,4 mi